| Margaret K Chally, MD | |
|
509 Biltmore Ave, Asheville, NC 28801-4601 | |
| (843) 237-3378 | |
| (843) 237-5073 |
| Full Name | Margaret K Chally |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 25 Years |
| Location | 509 Biltmore Ave, Asheville, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497718910 | NPI | - | NPPES |
| 140RK | Other | NC | BCBS |
| 5901964 | Medicaid | NC | |
| P00273492 | Other | NC | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 200500401 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Mission Hospital And Asheville Surgery Ce | Asheville, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Coverage Corp | 3072412592 | 364 |
News Archive
Based on research using a new mouse model of gastritis and stomach cancer, researchers from the Massachusetts Institute of Technology (MIT) say that prompt treatment of Helicobacter pylori (H. pylori) infections reverses damage to the lining of the stomach that can lead to cancer.
The medical community may be inadvertently creating a new generation of illegal, recreational drug users by prescribing anti-anxiety or sleep medications to teenagers, say University of Michigan researchers.
Ulcerative colitis (UC) and Crohn's disease (CD) are both relapsing and remitting chronic diseases of bowel inflammation. By that I mean they flare and physicians try to get the flare under control and try to induce remission. However, despite a number of treatments available, they tend to relapse.
Gilead Sciences, Inc. today announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive ambrisentan.
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced the submission of Impax's New Drug Application (NDA) for IPX066 to the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic Parkinson's disease (PD). IPX066 is a patented extended release capsule formulation of carbidopa-levodopa.
› Verified 5 days ago
| Entity Name | Carolina Mountain Emergency Medicine Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457317620 PECOS PAC ID: 0345223798 Enrollment ID: O20040608001059 |
News Archive
Based on research using a new mouse model of gastritis and stomach cancer, researchers from the Massachusetts Institute of Technology (MIT) say that prompt treatment of Helicobacter pylori (H. pylori) infections reverses damage to the lining of the stomach that can lead to cancer.
The medical community may be inadvertently creating a new generation of illegal, recreational drug users by prescribing anti-anxiety or sleep medications to teenagers, say University of Michigan researchers.
Ulcerative colitis (UC) and Crohn's disease (CD) are both relapsing and remitting chronic diseases of bowel inflammation. By that I mean they flare and physicians try to get the flare under control and try to induce remission. However, despite a number of treatments available, they tend to relapse.
Gilead Sciences, Inc. today announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive ambrisentan.
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced the submission of Impax's New Drug Application (NDA) for IPX066 to the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic Parkinson's disease (PD). IPX066 is a patented extended release capsule formulation of carbidopa-levodopa.
› Verified 5 days ago
| Entity Name | Emergency Coverage Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427005008 PECOS PAC ID: 3072412592 Enrollment ID: O20100202000365 |
News Archive
Based on research using a new mouse model of gastritis and stomach cancer, researchers from the Massachusetts Institute of Technology (MIT) say that prompt treatment of Helicobacter pylori (H. pylori) infections reverses damage to the lining of the stomach that can lead to cancer.
The medical community may be inadvertently creating a new generation of illegal, recreational drug users by prescribing anti-anxiety or sleep medications to teenagers, say University of Michigan researchers.
Ulcerative colitis (UC) and Crohn's disease (CD) are both relapsing and remitting chronic diseases of bowel inflammation. By that I mean they flare and physicians try to get the flare under control and try to induce remission. However, despite a number of treatments available, they tend to relapse.
Gilead Sciences, Inc. today announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive ambrisentan.
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced the submission of Impax's New Drug Application (NDA) for IPX066 to the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic Parkinson's disease (PD). IPX066 is a patented extended release capsule formulation of carbidopa-levodopa.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Margaret K Chally, MD Po Box 1856, Pawleys Island, SC 29585-1856 Ph: (843) 237-3378 | Margaret K Chally, MD 509 Biltmore Ave, Asheville, NC 28801-4601 Ph: (843) 237-3378 |
News Archive
Based on research using a new mouse model of gastritis and stomach cancer, researchers from the Massachusetts Institute of Technology (MIT) say that prompt treatment of Helicobacter pylori (H. pylori) infections reverses damage to the lining of the stomach that can lead to cancer.
The medical community may be inadvertently creating a new generation of illegal, recreational drug users by prescribing anti-anxiety or sleep medications to teenagers, say University of Michigan researchers.
Ulcerative colitis (UC) and Crohn's disease (CD) are both relapsing and remitting chronic diseases of bowel inflammation. By that I mean they flare and physicians try to get the flare under control and try to induce remission. However, despite a number of treatments available, they tend to relapse.
Gilead Sciences, Inc. today announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive ambrisentan.
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced the submission of Impax's New Drug Application (NDA) for IPX066 to the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic Parkinson's disease (PD). IPX066 is a patented extended release capsule formulation of carbidopa-levodopa.
› Verified 5 days ago
Vanessa C Peluso, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1100 Tunnel Rd, Asheville, NC 28805 Phone: 828-298-7911 | |
Dr. Elizabeth T Mccarty, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 Patton Ave, Asheville, NC 28806 Phone: 828-620-0876 | |
Terrence W Burt, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 843-237-3378 Fax: 843-237-5073 | |
Cody Russell, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-213-1111 | |
Dominic Fredrick Tutera, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-257-4472 | |
Krystin Thomas, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-213-1111 | |
Christopher Foster, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-213-1948 Fax: 828-213-1950 |